Nimorazole,a nitroimidazole anti-infective, is a hypoxic radiosensitizer potentially useful in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Nimorazole significantly improves the effect of radiotherapeutic management of supraglottic and pharynx tumors and can be given without major side-effects. Nimorazole is the only such chemical reagent that has shown a significant effect in a randomized controlled trial in head and neck cancer.
理化性质和储存条件
| Molecular Weight (MW) | 226.23 |
|---|
| Formula | C9H14N4O3 |
|---|
| CAS No. | 6506-37-2 |
|---|
| Storage | -20℃ for 3 years in powder form |
|---|
| -80℃ for 2 years in solvent |
| Solubility (In vitro) | DMSO:>30 mg/mL |
|---|
| Water: N/A |
| Ethanol: N/A |
| SMILES Code | O=[N+](C1=CN=CN1CCN2CCOCC2)[O-] |
|---|
| Synonyms | Nimorazole; K-1900; K 1900; K1900 |
|---|
实验参考方法
| In Vitro | In vitro activity: Nimorazole,a nitroimidazole anti-infective, is a hypoxic radiosensitizer potentially useful in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Nimorazole significantly improves the effect of radiotherapeutic management of supraglottic and pharynx tumors and can be given without major side-effects. Nimorazole is the only such chemical reagent that has shown a significant effect in a randomized controlled trial in head and neck cancer. |
|---|
| In Vivo |
|
|---|
| Animal model |
|
|---|
| Formulation & Dosage |
|
|---|
| References | Radiother Oncol. 2003 Jan;66(1):65-70. |
|---|
